Ruxolitinib after Stem Cell Transplant for T-cell Lymphoma
This study is testing if ruxolitinib, a medication, can help prevent T-cell lymphoma from coming back and reduce graft-versus-host disease (GVHD) after a stem cell transplant. GVHD happens when the donor cells attack your body. Ruxolitinib works by calming down the immune system and blocking cancer cell growth. We are looking for adults (18 and older) with T-cell lymphoma who are in partial or complete remission after their stem cell transplant. The main goals are to see how well ruxolitinib prevents relapse and improves survival without GVHD or relapse one year after the transplant. The study status is currently unclear, and we plan to enroll 44 participants.
- Study design
- This is an interventional study, but the phase is not specified. It plans to enroll 44 participants.
- What's involved
- You would take ruxolitinib orally twice daily. You would also undergo PET-CT scans, bone marrow biopsies, tissue biopsies, and blood sample collections.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study measures outcomes at 1-year post-transplant, suggesting follow-up for at least that duration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
At a glance
Conditions
NCT07356245
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Ohio State University Comprehensive Cancer Center
Columbus, Ohiostudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jonathan Brammer, MD · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Cumulative Incidence (CI) of relapseat 1-year post-auto-SCT
Relapse is defined as evidence of disease progression or recurrence based on Lugano criteria or confirmed by biopsy.
- GvHD and relapse free-survival (GRFS)at 1-year post-allo-SCT
GRFS is a composite endpoint of survival without grade III-IV acute GVHD, systemic therapy-requiring chronic GVHD (cGVHD), relapse, or death. Will be evaluated using the Kaplan-Meier method, with median survival and probability of surviving to relevant time points reported with point estimates and 90% confidence intervals separately for each study cohort. Comparisons to Center for International Blood and Marrow Transplant Research (CIBMTR) patients will use log-rank tests.